Pharmacotherapy and Adverse Effects

Dosage strategies

Standard dose (wide margin — OCPs, penicillin) · Regulated dose (measurable endpoint — BP, glucose, INR; no plasma monitoring needed) · Target level dose (plasma level correlates with effect but response itself unmeasurable — antiepileptics, digoxin) · Titrated dose (max effect limited by toxicity — anticancer, corticosteroids, levodopa).

Child dose: BW-based (BW/70 × adult dose) more practical than BSA-based (BSA/1.7 × adult dose, theoretically better but only used for anticancer drugs).

Factors modifying drug action

Age: Neonates — immature GFR+tubular secretion (renally-cleared drug t½ ↑3-5×), immature hepatic metabolism (chloramphenicol → grey baby syndrome), permeable BBB (unconjugated bilirubin → kernicterus), ↓gastric acidity+slow transit but FAST transdermal/rectal absorption (rectal diazepam for febrile seizures <5yr). Post-infancy: FASTER metabolism than adults (theophylline, phenytoin, carbamazepine — shorter t½, need higher mg/kg). Child-specific ADRs: corticosteroids→growth suppression, androgens→early epiphyseal fusion, tetracycline→tooth discoloration, phenothiazines→dystonia.

Elderly: ↓GFR (75% at 50, 50% at 75) · ↓hepatic enzyme activity+blood flow · ↓gut motility → slow absorption · ↓albumin · altered adrenergic receptor response · digitalis intolerance · anticholinergics→urinary retention (BPH). Higher ADR incidence overall (+ polypharmacy compounds interaction risk).

Sex/pregnancy: ♀ smaller size→lower dose range. Gynaecomastia = MALE-only ADR (ketoconazole, metoclopramide, digitalis). Pregnancy: ↓GI motility(↓absorption) · ↑plasma/ECF volume(↑Vd) · ↓albumin/↑α1-glycoprotein(altered free fractions) · ↑renal blood flow(faster clearance) · hepatic induction(faster metabolism) — net effect often unpredictable.

Genetics: 4-6× dose variation possible. CYP2C9 slow variants→warfarin bleeding risk. TPMT deficiency→severe marrow toxicity with azathioprine/6-MP. (See also G6PD, acetylator status under PK topic.)

Cumulation: slow-elimination drugs accumulate even without dosing error — chloroquine retinal toxicity; don’t repeat digoxin loading dose within a week of the last one.

Tolerance / Tachyphylaxis

Tolerance = ↑dose needed for same effect. Natural (inherent — rabbits/atropine) vs Acquired (develops with repeated use — most CNS depressants). NOT uniform across all actions of one drug: chlorpromazine tolerance to sedation but NOT antipsychotic effect; phenobarbitone tolerance to sedation but NOT antiepileptic effect; morphine tolerance to analgesia/euphoria but NOT constipation/miosis. Exceptions with minimal tolerance: atropine, digoxin, cocaine, nitroprusside.

Mechanisms: Pharmacokinetic (↑own metabolism — barbiturates, carbamazepine) vs Pharmacodynamic/cellular (receptor desensitization/downregulation).

Cross-tolerance: extends to related drugs without prior exposure — closer drugs=more complete (morphine-pethidine complete; morphine-barbiturates partial).

Tachyphylaxis: RAPID tolerance within quick-succession doses — indirectly-acting drugs depleting a limited store (ephedrine, tyramine, nicotine — release > synthesis).

Drug resistance = microbial tolerance to antimicrobials (different from host tolerance).

Clinical trial phases

Fixed-Dose Combinations

Pros: compliance, cost, genuine synergy (cotrimoxazole, levodopa+carbidopa), counteracts side effect (thiazide+K-sparing), prevents partial-regimen resistance (TB/HIV/malaria). Cons: unneeded components, can’t individualize doses, mismatched PK, ADR hard to attribute, one contraindication blocks whole product. Only ~25 WHO/20 India FDCs considered rational.

ADR classification

ADR = noxious, drug-related, at normal doses, needs action (excludes trivial effects/overdose). ADE = any untoward event during therapy, causality NOT implied (record first, assess later).

Type A (Augmented): exaggerated known pharmacology, dose-related, common, preventable/reversible. Type B (Bizarre): patient-specific, NOT dose-related, less common, MORE serious, needs drug withdrawal (allergy, idiosyncrasy).

Severity: Minor → Moderate (Rx change/+1 day stay) → Severe (life-threatening/permanent damage) → Lethal.

Categories: Side effects (unavoidable, therapeutic dose, e.g. prazosin→postural hypotension→fall) · Secondary effects (indirect — tetracycline→superinfection, steroids→reactivate TB) · Toxic effects (true overdose, absolute or relative-e.g. normal gentamicin dose in renal failure; may be extension of therapeutic effect itself — digoxin→heart block, OR unrelated action — morphine→resp depression, streptomycin→vestibular damage).

Poisoning management (A→H)

Hospitalize → Airway (lateral position, cuffed ETT if comatose) → Breathing (O2, ventilate) → Circulation (pulse/BP/IV line) → prevent further Absorption (fresh air/wash skin/gastric lavage within 2-3h + activated charcoal) → hasten Elimination (diuresis, urinary pH change, dialysis) → Symptomatic tx (IV diazepam for seizures) → Homeostasis (fluid/electrolyte/acid-base).

Lavage/emesis contraindicated: coma without airway protection, corrosives/kerosene(aspiration), CNS stimulants, >2h post-ingestion. Charcoal does NOT adsorb: strong acid/alkali, metals, iodine, cyanide, alcohols, hydrocarbons.

Antidotes: OP/carbamates→atropine · opioids→naloxone · atropine→physostigmine · BZDs→flumazenil · cyanide→Na nitrite+Na thiosulphate · methanol→fomepizole/ethanol · paracetamol→N-acetylcysteine · heparin→protamine · warfarin→vit K1 · iron→desferrioxamine · alkali→dilute acetic acid.

Intolerance & Idiosyncrasy

Intolerance = converse of tolerance, low threshold individual (extreme tail of normal distribution) — single dose triflupromazine→dystonia. Idiosyncrasy = genetically-determined abnormal reaction, restricted to specific genotype — chloramphenicol→aplastic anaemia (classic, non-dose-related, rare).

Drug allergy — Types I-IV

Anaphylaxis management: recline + O2 + IM adrenaline 0.5mg (ONLY life-saving step, repeat q5-10min) → H1 antihistamine (adjuvant) → IV hydrocortisone (slow onset, prevents biphasic reaction). Glucocorticoids = the effective drug for Type II/III/IV specifically (not Type I acutely — that’s adrenaline’s job).

Photosensitivity: Phototoxic (direct photochemical burn, fast, dose-related — tetracyclines) vs Photoallergic (immune, delayed, can spread beyond exposed area — sulfonamides, phenothiazines, thiazides).

Dependence, addiction, withdrawal

Dependence (was “physical dependence”) = neuroadaptation, needs continued drug presence, stopping→withdrawal syndrome. Addiction (was “psychological dependence”) = compulsive drug-seeking, overrides priorities, relapse-prone. INDEPENDENT of dependence (amphetamines/cocaine/cannabis/LSD = addicting, minimal dependence; nalorphine = dependence, minimal addiction). Reinforcement: faster route (inhaled, IV) = more reinforcing = bigger “high.”

Withdrawal also occurs with ordinary therapeutic drugs, not just addictive ones: corticosteroids→acute adrenal insufficiency · clonidine→rebound HTN+sympathetic overactivity · β-blockers→angina/MI · antiepileptics→↑seizures. Always TAPER, never stop abruptly.

Teratogenicity

Placenta = NOT a strict barrier — any drug can cross to some degree.

Stages: Fertilization/implantation (day 0-17) → early pregnancy loss (often unnoticed) · Organogenesis (day 18-55) = MOST vulnerable, structural malformations · Growth/development (day 56+) → functional abnormalities (ACE-I→renal/pulmonary hypoplasia, NSAIDs→premature ductus closure).

Thalidomide disaster (1958-61) — phocomelia, triggered modern teratogenicity regulation.

Key pairs: thalidomide→phocomelia · warfarin→embryopathy + vaginal carcinoma in female offspring · phenytoin→deformed teeth/retarded bone growth · valproate→neural tube defects · tetracycline→tooth discoloration · isotretinoin→craniofacial/cardiac/CNS defects · lithium→cardiac defects · ACE-I→renal/pulmonary hypoplasia.

Spontaneous malformation rate ~2% baseline — makes individual causation hard to prove. Default: avoid ALL non-essential drugs in pregnancy regardless of category.

Mutagenicity/Carcinogenicity

Reactive drug-oxidation intermediates → DNA damage → heritable mutation (mutagenic) or, if proto-oncogenes affected, malignancy (carcinogenic, takes 10-40yr to manifest). Implicated: anticancer drugs, radioisotopes, estrogens.

Iatrogenic disease

Persists even after drug withdrawn. NSAIDs/steroids→peptic ulcer · phenothiazines→drug-induced parkinsonism · isoniazid→hepatitis · hydralazine→drug-induced SLE.

Pharmacovigilance

WHO definition: detect+assess+understand+prevent ADRs. India: CDSCO. International: Uppsala Monitoring Centre (Sweden). Voluntary reporting is UNDER-USED (~10% even in developed countries) and skews toward immediate/dramatic reactions.

Causality assessment (Naranjo algorithm): temporal relationship · prior knowledge · dechallenge (resolves on stopping?) · rechallenge (recurs on restart? — often unethical, rarely done). Graded: Definite/Probable/Possible/Doubtful — NOT binary yes/no.

Clinical relevance

Type A vs Type B classification directly drives management: Type A → reduce dose, continue. Type B → stop, don’t rechallenge without specific reason. This single distinction is the fastest bedside decision tool for any new adverse effect.

Drug Dosage and Individualization

A dose is the amount of a drug needed to produce a defined degree of response in a given patient — and that qualifier matters, because the same drug has different doses for different purposes (aspirin: ~0.3–0.6 g as an analgesic, 60–150 mg/day as an antiplatelet, 3–5 g/day as an anti-inflammatory in rheumatoid arthritis).

Strategies for dosing vary by how easily the drug’s effect can be tracked:

• Standard dose — one dose suits nearly all patients, either because individual variation is small or the drug has a wide enough safety margin to cover it (oral contraceptives, penicillin, chloroquine).
• Regulated dose — the drug modifies an easily and repeatedly measurable physiological parameter, so dosage is titrated against that measurement directly (antihypertensives against blood pressure, hypoglycaemics against blood glucose, anticoagulants against INR); plasma drug level monitoring is not needed here.
• Target level dose — the response itself is not easily measurable, but a target plasma concentration range is known to correlate with benefit; an empirical starting dose is given and refined by monitoring plasma levels where available (antiepileptics, digoxin, theophylline).
• Titrated dose — the maximal therapeutic response cannot be used as the target because of intolerable adverse effects; dose is titrated upward from a low starting point until an acceptable balance of benefit and tolerability is found (anticancer drugs, corticosteroids, levodopa).

Dose calculation for children and unusually sized adults most often uses body weight (individual dose = BW/70 × average adult dose); body surface area is theoretically more accurate — since total body water, extracellular fluid, and metabolic rate track BSA more closely than weight alone — but is only actually used for a handful of drug classes (chiefly anticancer drugs) because of the extra complexity and thinner supporting data for most other drugs.

Factors Modifying Drug Action

Variation in response — between different patients, and even in the same patient on different occasions — is the rule, not the exception. Sources of variation fall into two broad effects: quantitative (plasma concentration or magnitude of action changes, correctable by dose adjustment) and qualitative (the type of response itself changes, as in allergy or idiosyncrasy — not correctable by dose adjustment at all).

Body size — dose is calculated on a body-weight or (less commonly) BSA basis for markedly over- or under-sized individuals, since the same absolute dose reaches a different effective concentration depending on distribution volume.

Age

• Neonates and infants are not simply small adults. Glomerular filtration and tubular secretion are immature at birth (reaching adult rates by roughly 5 and 7 months respectively), prolonging the half-life of renally eliminated drugs 3–5 fold; hepatic drug-metabolizing capacity is also immature, which is precisely why chloramphenicol causes grey baby syndrome in neonates — inadequate glucuronidation lets the drug accumulate to cardiovascular-collapse-inducing levels. The blood-brain barrier is more permeable in neonates (unconjugated bilirubin entering the brain causes kernicterus). Absorption differs too: gastric acidity is lower and intestinal transit slower, but transdermal absorption is faster (thinner skin) and rectal absorption is fast and reliable — the pharmacological basis for using rectal diazepam to control febrile seizures in children under 5. After infancy, hepatic metabolism is often faster than in adults, shortening half-life for drugs like theophylline, phenytoin, and carbamazepine, and requiring a relatively higher mg/kg dose for drugs cleared unchanged by the kidney. Children are also susceptible to age-specific adverse effects not relevant in adults: growth suppression from corticosteroids, premature epiphyseal fusion from androgens, tooth discoloration from tetracyclines deposited in developing enamel, and a higher rate of dystonic reactions to phenothiazines.
• The elderly show progressively declining renal function (GFR roughly 75% of young-adult values by age 50, roughly 50% by age 75), reduced hepatic microsomal activity and hepatic blood flow, reduced gut motility and intestinal blood flow (slower absorption), lower plasma albumin (altering free-drug fraction), and altered — usually reduced — adrenergic receptor responsiveness to both agonists and antagonists. The combined effect is a much higher incidence of adverse drug reactions in this age group, compounded by the fact that elderly patients are commonly on multiple concurrent drugs for several chronic conditions, multiplying interaction risk. Practical consequences worth naming: reduced streptomycin dose after age 50/70, relative intolerance to digitalis, and anticholinergic drugs precipitating urinary retention in men with prostatic hypertrophy.

Sex — women generally need doses toward the lower end of the standard range given smaller average body size; several adverse effects are sex-restricted by their mechanism (gynaecomastia from ketoconazole/metoclopramide/digitalis occurs only in men; several antihypertensives — clonidine, methyldopa, β-blockers, diuretics — impair sexual function specifically in men). Pregnancy alters drug disposition on several fronts simultaneously: reduced GI motility slows oral absorption, expanded plasma/extracellular volume raises Vd for many drugs, falling albumin (raising free acidic-drug fraction) alongside rising α1-acid glycoprotein (lowering free basic-drug fraction), increased renal blood flow speeds elimination of polar drugs, and hepatic enzyme induction speeds metabolism of many others — the net effect on any individual drug is often difficult to predict from first principles alone.

Species and race — inter-species differences (rabbits resistant to atropine, rodents resistant to digitalis) matter mainly for interpreting animal toxicology data; inter-racial differences are real in humans too (Black patients typically need higher, Mongoloid patients lower, atropine/ephedrine concentrations to dilate the pupil; β-blockers are less effective antihypertensives in Afro-Caribbean populations) and are part of the reasoning behind the Constitution’s broader point that population-specific data matters, not just mechanism.

Genetics (pharmacogenetics/pharmacogenomics) — dose needed for the same effect can vary 4–6 fold between individuals purely on a genetic basis, since every determinant of drug handling (transporters, metabolizing enzymes, ion channels, receptors) is under genetic control. Pharmacogenetics studies this variability; pharmacogenomics is the applied use of that genetic information to individualize drug and dose choice — the basis of the “personalized medicine” goal. Concrete, testable examples: slow-acetylator and fast-acetylator status for isoniazid (covered under Pharmacokinetics), low-activity CYP2C9 variants metabolizing warfarin slowly and raising bleeding risk, thiopurine methyltransferase (TPMT) deficiency raising the risk of severe bone marrow toxicity with azathioprine/6-mercaptopurine, and G6PD deficiency (also covered under Pharmacokinetics) precipitating haemolysis with oxidant drugs.

Concurrent disease and other drugs (drug interactions) are further sources of variation, covered under Pharmacokinetics (protein binding, enzyme induction/inhibition, renal/hepatic clearance changes) and Pharmacodynamics (synergism, antagonism) respectively — this topic does not repeat that material, only notes that both are genuine, common contributors to inter-individual variability alongside the factors above.

Cumulation — any drug accumulates if given faster than it is eliminated; slowly eliminated drugs are particularly prone to cumulative toxicity on chronic dosing even without any dosing error (chloroquine retinal damage with prolonged use; a full digoxin loading dose should not be repeated if the patient has already received one within the past week).

Tolerance, Cross-Tolerance, and Tachyphylaxis

Tolerance is the requirement of a progressively higher dose to reproduce a given response — a widely occurring adaptive phenomenon, not a defect.

• Natural tolerance — inherent, present from the first dose (rabbits tolerant to atropine; some individuals inherently hypo-responsive to alcohol or to β-blockers).
• Acquired tolerance — develops with repeated use in a previously responsive individual; most easily observed with CNS depressants, and favoured by uninterrupted drug presence in the body. Notably, some drugs show little or no significant tolerance at all — atropine, digoxin, cocaine, sodium nitroprusside.
• Tolerance does not develop uniformly across all of a drug’s actions, which is clinically important: tolerance develops to chlorpromazine’s sedative effect but not its antipsychotic effect; to phenobarbitone’s sedative effect but not (as much) its antiepileptic effect; to morphine’s analgesic and euphoric effects but much less to its constipating and miotic effects. This selective tolerance can shift a drug’s therapeutic index up or down over the course of treatment, not just its required dose.

Mechanisms: pharmacokinetic (drug-disposition) tolerance — chronic use enhances the drug’s own elimination (barbiturates and carbamazepine inducing their own metabolism); pharmacodynamic (cellular) tolerance — the target tissue itself becomes less responsive, via receptor desensitization or downregulation, or weakened downstream signal transduction.

Cross-tolerance is tolerance extending to pharmacologically related drugs even without prior exposure to them — the closer the relationship, the more complete the cross-tolerance (alcoholics show tolerance to barbiturates and general anaesthetics; morphine and pethidine show complete cross-tolerance, morphine and barbiturates only partial).

Tachyphylaxis is rapid tolerance developing within a short succession of doses given close together, rather than over weeks of chronic use. It is characteristically seen with indirectly acting drugs whose action depends on releasing a limited endogenous store — ephedrine, tyramine, nicotine all release catecholamines faster than synthesis can replace them, so repeated doses in quick succession progressively deplete the releasable store and respond less each time.

Drug resistance is the microbial analogue of tolerance — acquired insensitivity of a pathogen (not the host) to an antimicrobial’s inhibitory action.

Clinical Trials and Drug Development

Before human trials, a candidate is tested in animals (pharmacological screening plus systematic toxicity testing under Good Laboratory Practice) to characterize its effects and estimate a safe starting human dose. Once a regulator issues an investigational new drug licence, testing proceeds through a standardized, logically escalating sequence, governed internationally by Good Clinical Practice guidelines and, in India, by Schedule Y of the Drugs and Cosmetics Rules:

• Phase 0 (microdosing) — an emerging, non-mandatory strategy: a subpharmacological dose (roughly 1/100th of the estimated human dose, or a 100 μg ceiling) is given to healthy volunteers purely to gather human pharmacokinetic data using ultrasensitive detection methods, before committing to full animal toxicology and Phase I — intended to weed out candidates with unsuitable human pharmacokinetics early, cheaply, and before the larger investment of later phases.
• Phase I (human pharmacology and safety) — the first-ever human exposure, in a closely monitored setting with resuscitative facilities on hand, usually in healthy volunteers dosed one at a time; establishes human pharmacokinetics for the first time and screens for dangerous effects on vital functions. Open label, no blinding.
• Phase II (therapeutic exploration and dose ranging) — 100–500 selected patients at a few centres; establishes therapeutic efficacy, dose range, and ceiling effect under controlled, often randomized and blinded conditions. A drug commonly gets dropped here if it fails to show the desired clinical efficacy.
• Phase III (therapeutic confirmation) — 500–3000 patients across many centres, randomized double-blind comparison against existing therapy; establishes the drug’s actual value relative to standard treatment and finalizes indications and use guidelines. A New Drug Application is submitted to the regulator on the strength of this phase; approval grants marketing permission.
• Phase IV (postmarketing surveillance) — after marketing, data is gathered from real-world prescribing on a much larger, unselected population. This is where uncommon or idiosyncratic adverse effects, effects only apparent after long-term use, and unsuspected drug interactions typically surface — precisely because Phase I–III populations are too small and too tightly selected (excluding children, the elderly, pregnant patients, and those with renal/hepatic disease) to detect rare events. New indications, additional dosage forms, and further study in these excluded special populations may also emerge at this stage — drug development, in a real sense, continues well after a drug reaches the market.

Fixed-Dose Combinations (FDCs)

An FDC combines two or more drugs at a fixed dose ratio in one formulation. Genuine advantages exist — better compliance, cost saving, exploiting a real pharmacodynamic synergy (sulfamethoxazole + trimethoprim, levodopa + carbidopa), one component counteracting the other’s side effect (thiazide + potassium-sparing diuretic), and — specifically for tuberculosis, HIV, and falciparum malaria — guaranteeing that a patient never inadvertently takes only one drug of a required multi-drug regimen, which would otherwise risk resistance.

But the disadvantages are substantial and explain why only a small minority of marketed FDCs are considered rational: a patient may not need every component (paying for and being exposed to unnecessary side effects), doses of individual components usually cannot be adjusted independently, components may have mismatched pharmacokinetics making a single dosing interval inappropriate for both, an adverse effect cannot be easily attributed to a specific component, and a contraindication to any single component contraindicates the whole product. The current WHO Essential Medicines List includes only 25 FDCs, and India’s own essential medicines list only 20 — against a vastly larger number actually marketed and promoted. Before prescribing any combination, the real question is simple: does the patient actually need every ingredient in it? If not, it should not be prescribed on the grounds of “convenience.”

Adverse Drug Effects

An adverse effect is any undesirable or unintended consequence of drug administration, spanning everything from trivial to fatal. The narrower term adverse drug reaction (ADR) specifically means a noxious effect suspected to be drug-related, occurring at doses normally used therapeutically, that requires treatment, dose reduction, or caution in future use — this definition deliberately excludes expected/trivial side effects and outright overdose/poisoning. A related but distinct term, adverse drug event (ADE), refers to any untoward medical occurrence during drug therapy without necessarily implying causality — used deliberately to capture everything first, before causality is assessed later against pooled data.

Type A (Augmented/predictable) vs Type B (Bizarre/unpredictable) reactions. Type A reactions are an exaggeration of the drug’s known pharmacological action — dose-related, common, and mostly preventable and reversible (side effects, toxic effects, withdrawal consequences). Type B reactions arise from patient-specific peculiarities rather than the drug’s known pharmacology — less common, often non-dose-related, generally more serious, and requiring the drug be withdrawn (allergy, idiosyncrasy) — though some can be anticipated and avoided if the patient’s genetic/phenotypic basis is known and testable in advance.

Severity grading: Minor (no therapy/antidote/prolonged hospitalization needed) → Moderate (requires a change in drug therapy or prolongs hospital stay by ≥1 day) → Severe (potentially life-threatening, causes permanent damage, or needs intensive treatment) → Lethal (contributes directly or indirectly to death).

Categories of Adverse Effects

1. Side effects — unwanted but often unavoidable pharmacodynamic effects occurring at ordinary therapeutic doses; usually mild but occasionally hazardous (prazosin’s postural hypotension causing a fall and femoral neck fracture in an elderly patient). A side effect can arise from the same action as the therapeutic effect (atropine’s antisecretory action is wanted for premedication, but the resulting dry mouth is unwanted) or from an unrelated action of the same drug entirely (promethazine’s antiallergic action is unrelated to the sedation it also causes). Context can even flip a side effect into the therapeutic effect for a different indication — codeine’s constipating “side effect” for a cough is the desired therapeutic effect in traveller’s diarrhoea.

2. Secondary effects — indirect consequences of the drug’s primary action rather than a direct pharmacological effect in their own right (tetracycline suppressing normal gut flora, permitting superinfection; corticosteroids weakening host defence, reactivating latent tuberculosis).

3. Toxic effects — the result of genuinely excessive pharmacological action, from either absolute overdosage (accidental, suicidal, homicidal) or relative overdosage (a normal gentamicin dose becoming toxic in a patient with renal failure who cannot clear it normally). Toxicity may simply be an extension of the therapeutic effect itself taken too far (barbiturate coma, digoxin-induced complete heart block, heparin-induced bleeding), or may come from an entirely different action of the same drug (morphine’s respiratory depression is unrelated to its analgesia; streptomycin’s vestibular damage is unrelated to its antitubercular action).

Poisoning Management

General principles, roughly following an A-to-H sequence: Hospitalize → secure Airway (lateral position, cuffed ET tube if comatose, aspirate secretions) → assess Breathing (oxygen, ventilation if needed) → assess Circulation (pulse, BP, IV access) → prevent further Absorption (fresh air for inhaled poisons; remove contaminated clothing and wash for contact poisons; gastric lavage within 2–3 hours for ingested poisons, followed by activated charcoal, which physically adsorbs many — though not all — toxins) → hasten Elimination of the absorbed fraction (forced diuresis, urinary pH manipulation, or haemodialysis for select drugs) → Symptomatic treatment (IV diazepam for convulsions, external cooling for hyperpyrexia) → maintain fluid/electrolyte/acid-base Homeostasis.

Gastric lavage/induced emesis is not universally appropriate — it is contraindicated in the comatose or haemodynamically unstable patient, in corrosive or kerosene/hydrocarbon poisoning (aspiration risk), in CNS stimulant poisoning, and is simply not useful if presentation is more than 2 hours after ingestion or the poison is known to be non-life-threatening. Activated charcoal similarly fails to adsorb strong acids/alkalies, metallic salts, iodine, cyanide, alcohols, and hydrocarbons — it is not a universal antidote.

A short list of specific antidotes worth knowing by pairing: organophosphates/carbamates → atropine; opioids → naloxone; atropine (belladonna poisoning) → physostigmine; benzodiazepines → flumazenil; cyanide → sodium nitrite + sodium thiosulphate; methanol/ethylene glycol → fomepizole or ethanol; paracetamol → N-acetylcysteine; heparin → protamine sulfate; warfarin → vitamin K1; iron → desferrioxamine; alkali ingestion → dilute acetic acid.

Intolerance and Idiosyncrasy

Intolerance is the converse of tolerance — a characteristic toxic effect appearing at ordinary therapeutic doses in a given individual, reflecting an inherently low threshold to the drug (a subject at the extreme sensitive tail of the normal population distribution): a single dose of triflupromazine causing dystonia, a few doses of carbamazepine causing ataxia.

Idiosyncrasy is a genetically determined abnormal reactivity — the drug interacts with some feature unique to that individual’s genotype and produces an uncharacteristic reaction restricted to people sharing that genotype (chloramphenicol’s rare, non-dose-related aplastic anaemia is the classic serious example). Some idiosyncratic reactions have no defined genetic basis yet identified but are grouped here anyway for their bizarre, individual-specific character.

Drug Allergy (Hypersensitivity)

An immunologically mediated reaction producing symptoms entirely unrelated to the drug’s pharmacodynamic profile — occurring in only a small fraction of exposed individuals, requiring prior sensitization (which may go unnoticed), and with severity poorly correlated to dose (even a trace amount can trigger a severe reaction in a sensitized person). The drug (or more often its metabolite, acting as an incomplete antigen/hapten bound to an endogenous protein) triggers antibody or sensitized-lymphocyte production.

Type II and III are both antibody-mediated but differ in where the antigen sits: Type II antibody targets antigen fixed to a cell surface (lysing that specific cell), Type III antibody binds circulating antigen to form complexes that deposit elsewhere (causing vasculitis wherever they lodge) — a frequently confused pair. Type IV involves no antibody at all; drawing one in is a direct factual error.

Managing anaphylaxis is the one true emergency in this list: reclining position, high-flow oxygen, and — the only genuinely life-saving measure — intramuscular adrenaline (0.5 mg for an adult, scaled down for children), repeated every 5–10 minutes if response is inadequate or transient. Adrenaline should not be given IV unless shock is immediately life-threatening, and if it must be, only heavily diluted (1:10,000 or 1:100,000) with continuous monitoring. An H1 antihistamine and IV glucocorticoid are useful adjuncts — the glucocorticoid acting too slowly to help acutely but valuable for preventing a delayed/biphasic reaction, and it is the only effective drug specifically for Type II, III, and IV reactions (which, unlike Type I, do not respond to adrenaline or antihistamines the same way).

Photosensitivity is a distinct cutaneous reaction to UV light exposure, sensitized by a drug: phototoxic reactions (a direct, non-immunological photochemical burn-like reaction — fast onset, dose-related, seen with tetracyclines) versus photoallergic reactions (a genuine cell-mediated immune response to light-altered drug, slower onset, can persist and spread beyond the exposed area — seen with sulfonamides, phenothiazines, thiazides).

Drug Dependence, Addiction, and Withdrawal

Dependence (formerly “physical dependence”) is an altered physiological state from repeated drug use that requires the drug’s continued presence to maintain equilibrium; stopping produces a characteristic, often mechanism-specific withdrawal syndrome. It reflects neuroadaptation, not a moral failing — the nervous system has genuinely reorganized around the drug’s presence.

Addiction (formerly “psychological dependence”) is a pattern of compulsive drug-seeking and use that overrides other priorities, with strong relapse tendency even after successful withdrawal — distinct from dependence, since some strongly addicting drugs (amphetamines, cocaine, cannabis, LSD) produce little physical dependence, while some dependence-producing drugs (nalorphine) produce little addictive drug-seeking behaviour.

Reinforcement is the drug’s capacity to produce effects the user wants repeated — faster-acting routes (inhaled, IV) are more reinforcing because the “high” is more intense, which is part of why route of administration matters as much as the drug itself in abuse potential.

Withdrawal is not limited to classically “addictive” drugs — abrupt cessation of several therapeutic drugs used entirely appropriately produces its own adverse consequences through the same adaptive mechanism: acute adrenal insufficiency after sudden corticosteroid withdrawal, severe rebound hypertension and sympathetic overactivity after stopping clonidine abruptly, worsening angina or precipitated MI after abrupt β-blocker withdrawal, and increased seizure frequency after sudden antiepileptic withdrawal. All are minimized by tapering rather than stopping abruptly — this is the same receptor-upregulation logic already covered under Pharmacodynamics for β-blockers specifically.

Teratogenicity

The capacity of a drug to cause foetal abnormality when given to a pregnant mother. The placenta is not a strict barrier — essentially any drug can cross it to some degree — so this risk is never fully excludable for any drug given in pregnancy.

Drug exposure has different consequences depending on the gestational stage: fertilization/implantation (conception to day 17) — exposure typically causes early pregnancy failure, which often goes unnoticed rather than producing a malformed birth; organogenesis (days 18–55) — the single most vulnerable window, where structural malformations are actually produced; growth and development (day 56 onward) — functional rather than structural abnormalities occur (ACE inhibitors causing renal/pulmonary hypoplasia, NSAIDs causing premature closure of the ductus arteriosus, androgens/progestins masculinizing a female foetus).

The thalidomide disaster (1958–61) is the historical event that made teratogenicity a formal part of drug regulation — thousands of infants born with phocomelia after maternal use of this sedative/anti-emetic in early pregnancy. Named human teratogens worth recognizing by drug-effect pairing: thalidomide (phocomelia), warfarin (a distinctive embryopathy and, notoriously, vaginal carcinoma in teenage female offspring exposed in utero), phenytoin (deformed teeth, retarded bone growth), sodium valproate (neural tube defects — see Pathophysiology of teratogenic drugs generally), tetracyclines (discoloured teeth, retarded bone growth in the foetus, virilization effects reported), isotretinoin (craniofacial, cardiac, and CNS defects), lithium (foetal cardiac defects, developmental delay), ACE inhibitors (renal/pulmonary hypoplasia), and stilboestrol (virilization, and reproductive tract malignancy risk in offspring).

Because spontaneous malformation already occurs in roughly 2% of all pregnancies with no drug involved, and most implicated drugs are only weak/low-grade teratogens, proving or disproving a specific drug’s teratogenic contribution in an individual case is often genuinely difficult — which is exactly why the safest clinical default is to avoid all non-essential drugs during pregnancy regardless of official risk category, rather than relying on a risk grading system alone.

Mutagenicity and Carcinogenicity

Reactive intermediates generated during drug oxidation can damage DNA directly, causing heritable mutations (mutagenicity) or, if the damage affects genes regulating cell growth (proto-oncogenes or their regulators), malignant transformation (carcinogenicity) — a process that typically takes 10–40 years to manifest clinically. Anticancer drugs, radioisotopes, and estrogens are among the drug classes implicated; agents showing clear mutagenic/carcinogenic potential are generally kept off the market unless their benefit in a life-threatening condition outweighs this risk.

Drug-Induced (Iatrogenic) Disease

A functional disturbance caused by a drug that persists even after the drug is withdrawn and eliminated — distinguishing it from an ordinary reversible adverse effect. Examples worth naming by pairing: NSAIDs/corticosteroids → peptic ulcer; phenothiazines/antipsychotics → drug-induced parkinsonism; isoniazid → hepatitis; hydralazine → drug-induced systemic lupus erythematosus.

Pharmacovigilance

Pharmacovigilance is the WHO-defined science of detecting, assessing, understanding, and preventing adverse drug effects and other drug-related problems, with the core aim of reducing drug-related harm and informing rational prescribing and regulatory decisions. Activities include voluntary ADR reporting by healthcare professionals (notoriously under-used — only around 10% of ADRs are reported even in developed countries, and reporting skews toward immediate, dramatic reactions), prescription event monitoring, dissemination of drug safety alerts, and — where warranted — labelling changes or market withdrawal. India’s national pharmacovigilance programme is coordinated by the CDSCO; the international coordinating body is the Uppsala Monitoring Centre in Sweden.

Causality assessment — since an adverse event during drug therapy is not automatically caused by the drug, causality is judged systematically using standardized tools (the Naranjo algorithm is the best known) against criteria including: temporal relationship (does the timing fit?), prior knowledge (has the drug been linked to this event before?), dechallenge (did the event resolve on stopping the drug?), and rechallenge (did it recur if the drug was cautiously restarted? — rarely done, since it can be unethical or dangerous). Results are graded as Definite, Probable, Possible, or Doubtful, rather than forced into a binary yes/no.

Rational Use of Medicines

The WHO defines rational medicine use as patients receiving medication appropriate to their clinical need, at a dose meeting their individual requirements, for an adequate period, at the lowest cost to themselves and the community. In practice, irrational prescribing is widespread everywhere, more so in resource-limited settings, and is shaped by more than just prescriber knowledge — role models (following senior/popular physicians’ habits), heavy patient load fostering routinized symptom-based prescribing, pressure to give prompt symptomatic relief, and imprecise diagnosis leading to “covering all bases” polypharmacy are all documented contributors independent of what the prescriber actually knows.

Clinical Relevance

The A/B reaction classification is not academic — it directly predicts what to do when an adverse effect occurs. A Type A reaction usually means “reduce the dose and continue”; a Type B reaction usually means “stop the drug and do not rechallenge without a specific reason to believe it’s safe.” Recognizing which pattern a given adverse effect fits — augmented pharmacology versus bizarre/allergic — is the single fastest way to decide whether a drug can be continued at a lower dose or must be abandoned entirely.

Diagram 1 — Poisoning Management Sequence (A to H)

What to draw: A vertical flowchart of the general management sequence for an acutely poisoned patient: Hospitalize → Airway → Breathing → Circulation → prevent further Absorption → hasten Elimination → Symptomatic treatment → Homeostasis (fluid/electrolyte/acid-base).

Labelling requirements: label each step with both its letter and its actual clinical action (not just “A” but “Airway — lateral position, cuffed ET tube if comatose”) — a bare mnemonic without the action beside it fails the “no unresolved placeholder” standard for a rapid-revision diagram.

Common exam-marking mistakes:

• Starting with decontamination before airway/breathing/circulation are secured — the ABC-first sequence is itself an examinable point, not just a memory aid.
• Listing gastric lavage/charcoal as universally appropriate without the contraindications (coma without airway protection, corrosive/hydrocarbon ingestion, presentation >2 hours post-ingestion).

Note on the Four Types of Drug Hypersensitivity Reactions

Not rendered as a diagram — a 4-way comparison across antibody/cell type, mechanism, mediators, manifestation, and time course is a table, not a flowchart, and is presented as one in notes.md. That table also carries the Type II/III distinction and the adrenaline-vs-glucocorticoid management point.

Diagram 2 — Clinical Trial Phases (0 to IV)

What to draw: A horizontal timeline with five stages in sequence — Phase 0 (microdosing) → Phase I (human pharmacology/safety) → Phase II (dose-ranging) → Phase III (therapeutic confirmation) → Phase IV (postmarketing surveillance) — each labelled with its approximate subject count and primary purpose.

Labelling requirements: subject numbers must be included at each phase (Phase I: single-digit-to-dozens of healthy volunteers; Phase II: 100–500 patients; Phase III: 500–3000 patients; Phase IV: unrestricted real-world population) — the escalating scale is itself the point, showing why rare adverse effects are only ever caught in Phase IV.

Common exam-marking mistakes:

• Describing Phase IV as merely “monitoring” without stating what it specifically catches that earlier phases structurally cannot — idiosyncratic/rare reactions, long-term-use effects, and interactions in populations (children, elderly, pregnant, renal/hepatic disease) that are excluded from Phases I–III by design.
• Omitting that a New Drug Application and marketing approval happen after Phase III, not after Phase IV — Phase IV occurs on an already-marketed drug, which is precisely why its findings can lead to a label change or withdrawal rather than a “failure to launch.”

Long Essays (5)

Short Essays (10)

Essays (13)

Short Answers (75)

Short Notes (10)

Multiple Choice Questions (24)